Expert opinion on drug metabolism & toxicology · 2015
Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Farhoudi Maryam, Khalili Hossein, Karimzadeh Iman, Abbasian Ladan
Аннотация
OBJECTIVE: To assess different aspects of potential drug-drug interactions (DDIs) including incidence, severity, level of evidence and probable associated factors in Iranian HIV-infected individuals receiving antiretroviral therapy.
METHODS: All adult HIV-infected patients under highly active antiretroviral therapy regimen attending a referral HIV clinic during 1 year were screened retrospectively for potential moderate or severe DDIs by the Lexi-Interact On-Desktop software.
RESULTS: Near seventy percent (69.89%) of detected DDIs in our population were major. The three most common detected potential DDIs were efavirenz + methadone (11 cases), lopinavir-ritonavir + sulfamethoxazole-trimethoprim, (10 cases) and lamivudine + ribavirin (7 cases). Lopinavir-ritonavir (27.96%) and citalopram (23.66%) were the most common offending antiretroviral and non-antiretroviral agents, respectively.
CONCLUSION: Performing multicenter and prospective studies is warranted to assess the real clinical as well as economic impacts of DDIs on HIV-infected patients receiving antiretroviral agents in our population and also to develop efficient preventive strategies.
METHODS: All adult HIV-infected patients under highly active antiretroviral therapy regimen attending a referral HIV clinic during 1 year were screened retrospectively for potential moderate or severe DDIs by the Lexi-Interact On-Desktop software.
RESULTS: Near seventy percent (69.89%) of detected DDIs in our population were major. The three most common detected potential DDIs were efavirenz + methadone (11 cases), lopinavir-ritonavir + sulfamethoxazole-trimethoprim, (10 cases) and lamivudine + ribavirin (7 cases). Lopinavir-ritonavir (27.96%) and citalopram (23.66%) were the most common offending antiretroviral and non-antiretroviral agents, respectively.
CONCLUSION: Performing multicenter and prospective studies is warranted to assess the real clinical as well as economic impacts of DDIs on HIV-infected patients receiving antiretroviral agents in our population and also to develop efficient preventive strategies.